WALTHAM, Mass. — September 30, 2025 — Leads & Copy — Upstream Bio, Inc. (Nasdaq: UPB) presented structural and mechanistic data at the European Respiratory Society (ERS) Congress showing verekitug’s potent pharmacodynamic activity through its unique approach of targeting the thymic stromal lymphopoietin (TSLP) receptor.
The data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites and outcompetes TSLP in the presence of preformed heterodimeric receptor complexes.
The findings support the potential of verekitug’s unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases.
Aaron Deykin, MD, Chief Medical Officer and Head of R&D of Upstream Bio, said the company continues to deepen its understanding of verekitug’s unique TSLP receptor-targeting mechanism and its role in driving the rapid and durable effects that have been demonstrated to date.
Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor and has demonstrated rapid, substantial, and sustained TSLP receptor inhibition for up to 24 weeks after the last dose in clinical trials.
A digital version of the presentation can be found on the Publications section of the Upstream Bio website.
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only known monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
Contact: Meggan Buckwell, Director, Corporate Communications and Investor Relations, ir@upstreambio.com
Source: Upstream Bio
